XNAS
SGHT
Market cap460mUSD
Oct 08, Last price
8.47USD
1D
0.00%
1Q
59.21%
IPO
-74.10%
Name
Sight Sciences Inc
Chart & performance
P/E
—
P/S
5.96
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.20%
Rev. gr., 5y
22.86%
Revenues
77m
-3.13%
Net income
-38m
L-25.40%
CFO
-30m
L+32.85%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Key people
Staffan Encrantz
Independent Chairman of the Board · since 2017
Manohar Raheja
Executive Vice President - Research and Development · since 2024
Brenton Taylor
Principal Operating Officer, Executive Vice President of Operations · since 2024
David Badawi
Co-Founder, Chief Technology Officer, Director · since 2011
Chief Operating Officer, Principal Operating Officer · since 2025
Chief Legal Officer · since 2020
Chief Commercial Officer · since 2023
Paul Badawi
President, Chief Executive Officer, Co-Founder, Director · since 2019
Independent Director · since 2025
Staffan Encrantz
Independent Chairman of the Board · since 2017
Independent Director · since 2022
Catherine Mazzacco
Independent Director · since 2023
Independent Director · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||